Clinical research jobs provider Bristol-Myers Squibb has announced its new atrial fibrillation (AF) therapy has been accepted for review by the US Food and Drug Administration.
Investigational compound Elquis has been submitted for a new drug application for the prevention of stroke and systemic embolism among patients with AF.
The requests were based on the results of two phase III trials that evaluated its efficacy and safety when tested on 24,000 patients in the largest completed clinical development programme for stroke prevention among people with AF.
Eliquis was previously validated for review by the European Medicines Agency, with the FDA accepting the filing and assigning a priority-review demonstration for the latest submission.
Earlier this month, the Bristol-Myers Squibb Foundation's Together on Diabetes initiative awarded $18.4 million (£11.7 million) to help the US communities that are affected by diabetes.
John Damonti, president of the company's charitable arm, said: "Type 2 diabetes is continuing to grow year to year in the US despite significant prevention and control efforts."